Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 1-2

  Vergote, Ignace ^a   Amant, Frederic ^a   Leunen, Karin ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; LAPAROSCOPY; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL PRACTICE; FEMALE; GYNECOLOGY; ONCOLOGY; OVARIAN NEOPLASMS; PROCEDURES;

CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 77956640361     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.011     Document Type: Editorial

References (11)

1. A. du Bois, M. Quinn, and T. Thigpen 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann. Oncol. Suppl 8 2005 viii7 viii12
2. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol. Oncol. 103 2006 1070 1076
3. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann. Surg. Oncol. 16 2009 2315 2320
4. I. Vergote, C.G. Tropé, and F.A. Amant Neoadjuvant chemotherapy or primary surgery in Stage IIIc-IV ovarian cancer NEJM 363 2010 943 953
5. S.B. Dewdney, B.J. Rimel, and A.J. Reinhart The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the society of gynecologic oncologists Gynecol. Oncol. 119 2010 18 21
6. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J. Clin. Oncol. 20 2002 Mar 1 1248 1259
7. D. Chi, E. Eisenhauer, J. Land, L. Haddad, N. Abu-Rustum, Y. Sonoda, D. Levine, M. Hensley, and R. Barakat What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103 2006 559 564
8. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 6 2009 Mar 15 1234 1244
9. S. Risum, C. Høgdall, and A. Loft Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-a prospective study Gynecol. Oncol. 108 2 2008 265 270
10. I. Vergote, S. Marquette, F. Amant, P. Berteloot, and P. Neven Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma Int. J. Gynecol. Cancer 15 2005 776 779
11. J.L. Brun, R. Rouzier, S. Uzan, and E. Daraï External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score Gynecol. Oncol. 110 2008 354 359